University of Tokyo
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Tokyo
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.